Navigation Links
Med-Emerg International Inc. receives court approval for AIM Health Group arrangement
Date:1/13/2009

TORONTO, Jan. 13 /PRNewswire-FirstCall/ - Med-Emerg International Inc. (OTCBB:MDER) ("MedEmerg"), one of Canada's leading providers of health services, is pleased to announce that it has obtained final court approval from the Ontario Superior Court of Justice approving the previously announced plan of arrangement (the "Arrangement") with AIM Health Group Inc. The Arrangement was approved by a special resolution of MedEmerg's shareholders at a special meeting of MedEmerg's shareholders held on January 8, 2009.

Subject to the satisfaction of certain closing conditions, the Arrangement is expected to close on or about January 15, 2009.

About Med-Emerg International Inc.

MedEmerg specializes in the coordination and delivery of health care services in Canada. These services include an integrated chronic pain management program, community-based infusion centers and health human resource management, including physician and nurse staffing.

MedEmerg's audited revenue for its fiscal year ended December 31, 2007 was approximately US$22 million.

(www.medemerg.com)

Caution Concerning Forward-Looking Statements

Certain statements in this press release are forward-looking statements, including, but not limited to, those relating to the proposed transaction, the timing of the closing of the proposed transaction and other statements that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "plan", "expect", "believe", "intend", "anticipate", "forecast", "target", "estimate" and similar expressions identify forward-looking statements. Forward-looking statements are based on assumptions made by and information currently available to MedEmerg. Investors are cautioned that these forward-looking statements are neither promises nor guarantees, and are s
'/>"/>

SOURCE MED-EMERG INTERNATIONAL INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Med-Emerg International Inc. reports improved income from continuing operations
2. Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc.
3. Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc.
4. International study strengthens case for daily calcium pill
5. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
6. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
7. LCA Hails International Investigators Studying Lung Cancer
8. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
9. PRA International Adds Dr. Susan Stansfield as Executive Vice President
10. Medical Services International Maintains Pace in Second Quarter
11. Clarity Imaging International, Inc. Rolls Out Mobile DEXA Program
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 1Delayed First Visit to Dentist Can Affect Childrens Lifelong Oral Health 58581 2Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 1Sleep Center at Baylor Dallas One of Select Centers in North Texas to Receive Accreditation 58576 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 1United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 2United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food 5114 3